SK partners with Hilleman Lab to develop advanced Ebola vaccine

2023. 11. 23. 15:36
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Courtesy of SK Bioscience]
SK Bioscience Co. and Hilleman Laboratories, a Singapore-based vaccine research organization., entered a memorandum of understanding (MOU) to jointly develop a second-generation Zaire Ebola virus vaccine, according to the South Korean biopharmaceutical firm on Wednesday.

Established in 2009, Hilleman Laboratories is an equal-joint venture between US drug maker Merck & Co. Inc. and British charitable foundation Wellcome Trust. The organization has been dedicated to developing programs for cost-effective use of vaccines in developing countries, as well as research and development for medicinal products.

The recent partnership will aim to develop an advanced vaccine for the Zaire Ebola virus. The two partners agreed to supply the vaccines to low-to-middle-income countries once the vaccine is successfully developed.

SK Bioscience will mass produce the vaccines at its plant in Andong, North Gyeongsang Province, for global supply.

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?